WHO ICTRP trial
A study to investigate subcutaneous isatuximab in combination with carfilzomib…
JPRN-jRCT2031220739 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031220739 |
|---|---|
| Public title | A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma |
| Scientific title | A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM) |
| Primary sponsor | Tanaka Tomoyuki |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Australia;Japan |
| Conditions | Relapsed/refractory multiple myeloma |
| Interventions | Drug: Isatuximab Pharmaceutical form: Solution for Subcutaneous administration, Route of administration: Subcutaneous Drug: Carfilzomib Pharmaceutical form: Powder for solution for infusion, Route of administration: Intravenous Drug… |
| Registration date | Mar 27, 2023 |
| Target size | 68 |
| Secondary IDs | NCT05704049 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: